Aminoglycoside-induced nephrotoxicity - A focus on monitoring: A review of literature

Journal of Pharmacy Practice

Volumn 27, Issue 6, 2014, Pages 562-566

  Destache, Christopher J ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycosides; enterococcal endocarditis; nephrotoxicity; resistant Enterobacteriaceae

Indexed keywords

AMINOGLYCOSIDE; GENTAMICIN;

ACINETOBACTER; ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; ENDOCARDITIS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; KIDNEY FAILURE; META ANALYSIS (TOPIC); NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATIENT IDENTIFICATION; PATIENT MONITORING; PATIENT RISK; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; CHEMICALLY INDUCED; KIDNEY DISEASE;

AMINOGLYCOSIDES; DRUG MONITORING; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 84910054239     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014546102     Document Type: Article

References (45)

1. Durante-Mangoni E, Grammatikos A, Utili R, et al. Do we still need the aminoglycosides?. Int J Antimicrob Agents. 2009 ; 33 (3). 201-205
2. Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007 ; 45 (6). 753-760
3. Baddour LM, Wilson WR, Bayer AS, et al. Committee on rheumatic fever, endocarditis, and Kawasaki disease: council on cardiovascular disease in the young: councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia: American heart association infectious diseases society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005 ; 111: e394 - e434
4. Noone P, Parsons TMC, Pattison JR, et al. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 ; 1 (5906). 477-481
5. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 ; 149 (3). 443-448
6. Zaske DE, Bootman JL, Solem LB, et al. Increased burn patient survival with individualized dosages of gentamicin. Surgery. 1982 ; 91 (2). 142-149
7. Jackson GG, Riff LJ. Pseudomonas bacteremia. Pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis. 1971 ; (124suppl). S185 - S191
8. Gilbert DN Principles and Practice of Infectious Diseases. 5 th ed). New York, NY: Churchill Livingstone; 2000:307-335. Mandell GL Bennett JE Dolin R, ed. New York, NY: Churchill Livingstone ; 2000: 307-335.
9. Bootman JL, Wertheimer AI, Zaske DE, et al. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci. 1978 ; 68 (3). 267-272
10. Destache CJ, Meyer SM, Bittner MB, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit. 1990 ; 12 (5). 419-426
11. Streetman DS, Nafziger AN, Destache CJ, et al. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001 ; 21 (4). 443-451
12. Barza M, Lauermann M. Why monitor serum levels of gentamicin?. Clin Pharmacokinet. 1978 ; 3 (3). 202-215
13. Dahlgren JG, Anderson ET, Hewitt WL. Gentamicin blood levels in regard to nephrotoxicity. Antimicrob Agents Chemother. 1975 ; 8 (1). 58-92
14. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995 ; 39 (3). 650-655
15. Nicolau DP, Wu AH, Finocchiaro S, et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monoit. 1996 ; 18 (3). 263-266
16. Freeman CD, Nicolau DP, Belliveau PP, et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997 ; 39 (6). 677-686
17. Prins JM, Weverling GJ, de Blok K, et al. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother. 1996 ; 40 (11). 2494-2499
18. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics. 2004 ; 114 (1). e111 - e118
19. Prayle A, Watson A, Fortnum H, et al. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 2010 ; 65 (7). 654-658
20. Fourmy D, Recht MI, Banchard SC, et al. Structure of the A site of Escherichia coli 16 S ribosomal RNA complexed with an aminoglycoside antibiotic. Science. 1996 ; 274 (5291). 1367-1371
21. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999 ; 43 (4). 727-737
22. Lingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999 ; 43 (5). 1003-1012
23. Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol. 2007 ; 223 (1). 86-98
24. Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metabol Pharmacokinet. 2004 ; 19 (3). 159-170
25. Silverblatt FJ, Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int. 1979 ; 15 (4). 335-345
26. Bowles SK, Schentag JJ Applied Pharmacokinetics Principles of Therapeutic Drug Monitoring. 2 nd ed. Spokane, WA: Applied Therapeutics, Inc.; 1986:283-398. Evans WE Schentag JJ Jusko WJ, ed. Spokane, WA: Applied Therapeutics, Inc ; 1986: 283-398.
27. Schmitz C, Hilpert J, Jacobsen C, et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem. 2002 ; 277 (1). 618-622
28. McWilliams SJ, Antoine DJ, Sabbisetti V, et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS One. 2012 ; 7 (8). e43809
29. Oliveira JF, Silva CA, Barbieri CD, et al. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009 ; 53 (7). 2887-2891
30. Raveh D, Kopyt M, Hite Y, et al. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM. 2002 ; 95 (5). 291-297
31. Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Safety. 2013 ; 36 (4). 217-230
32. Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycoside: a controlled trial. Am J Med. 2003 ; 114 (3). 194-198
33. Barza M, Ionnidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. Br Med J. 1996 ; 312 (7027). 338-345
34. Fisman DN, Kaye KM. Once-daily dosing of aminoglycoside antibiotics. Infect Dis Clin North Am. 2000 ; 14 (2). 475-487
35. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999 ; 43 (7). 1549-1555
36. Sanchez-Alcaraz A, Vargas A, Quintana MB, et al. Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. J Clin Pharm Ther. 1998 ; 23 (5). 367-373
37. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf. 1997 ; 16 (3). 205-231
38. Bertino JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993 ; 167 (1). 173-179
39. Cannella CA, Wilkerson ST. Acute renal failure associated with inhaled tobramycin. Am J Health Syst Pharm. 2006 ; 63 (19). 1858-1861
40. Izquierdo MJ, Gomez-Alamillo C, Ortiz F, et al. Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. Clin Nephrol. 2006 ; 66 (6). 464-467
41. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA. 1995 ; 274 (21). 1706-1713
42. Tam VH, Preston SL, Briceland LL. Once-daily aminoglycosides in the treatment of gram-positive endocarditis. Ann Pharm. 1999 ; 33 (5). 600-606
43. Miro JM, Pericas JM, del Rio A. A new era for treating Enterococcus faecalis endocarditis: ampicillin plus short course gentamicin or ampicillin plus ceftriaxone: that is the question!. Circulation. 2013 ; 127 (17). 1763-1766
44. Mainardi JL, Gutmann L, Acar JF, et al. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother. 1995 ; 39 (9). 1984-1987
45. Fernandez-Hidalgo N, Almirante B, Gavalda J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013 ; 56 (9). 1261-1268